Before the ring of the bell today, Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company, has been seeing a 30.24% jump in its stock price. At the close of the previous session, the stock was up 16.43% to close at $2.48. Over the past 5 sessions, the stock is down -8.49% while the decline increases to -36.25% for the month. The stock has added 125.45% in the past year whereas its year-to-date performance stands at a gain of 161.05%.
There has been no directly related news to drive that momentum, but the recent developments may also be an indicator of how the company is currently performing.
Read More
- The Top Cryptocurrency Stocks Flight in the Market for long-term
- Top 3 Cloud Computing Stocks to Watch For in 2021
Recent developments:
Atossa Therapeutics is dedicated to discovering and developing innovative drugs in the oncology and infectious disease fields. At present, the company is focusing its efforts on COVID-19 and breast cancer.
Last month, Atossa Therapeutics announced results from its Phase 1 double-blind, randomized, placebo-controlled clinical study using AT-301, Atossa’s proprietary nasal spray candidate.
- A total of two different dose levels of AT-301 were tested over a 14-day period in healthy males and females in this study.
- For newly diagnosed patients with COVID-19, AT-301 is being developed for at-home use.
- Current FDA-approved treatments to treat COVID-19 cannot be used at home.
- According to the studies’ final data analysis, no serious adverse events, no discontinuations, no bronchospasms were observed.
- All subjects but one was observed to have adverse effects, which were found to be moderate in severity whereas all other adverse effects were milder.
- AT-301 nasal spray was well tolerated in this study and was deemed safe by Atossa.
- AT-301 has been associated with nasal discomfort and sneezing as the most common treatment-related adverse events when administered in either a single or multiple doses.
